Celiac Panel: What Your Results Actually Mean for Women

Why the Celiac Panel Matters More for Women

Celiac disease affects roughly 1 in 100 people globally, but women receive a diagnosis at approximately twice the rate of men and are more likely to present with atypical symptoms rather than classic gastrointestinal complaints. A landmark 2015 study in BMJ found that the average time from symptom onset to celiac diagnosis in women is 6.4 years, compared with 4.7 years in men, partly because fatigue, anemia, and mood changes are attributed to hormonal causes first.

For you as a woman, the stakes of a missed diagnosis are high. Undiagnosed celiac disease is associated with iron-deficiency anemia, folate and B12 depletion affecting fetal neural tube development, reduced bone mineral density, and a threefold increased risk of miscarriage. Knowing what the test measures, how to prepare correctly, and how to interpret the numbers can meaningfully change your health trajectory.

What the Panel Includes

A standard celiac panel ordered in the United States typically contains:

• tTG-IgA (tissue transglutaminase IgA antibody): the first-line screening test
• Total serum IgA: rules out IgA deficiency, which causes false-negative tTG-IgA results
• EMA-IgA (endomysial antibody IgA): high specificity, used for confirmation
• DGP-IgG and DGP-IgA (deamidated gliadin peptide antibodies): used when IgA deficiency is present or in young children

ACG Clinical Guidelines (2023) recommend tTG-IgA as the single best initial test in adults with an intact IgA system, with total IgA measured simultaneously to validate the result.

The Sex Difference You Are Not Usually Told About

Women with celiac disease are more likely than men to present with anemia, osteoporosis, and reproductive complications rather than diarrhea. A 2019 analysis in Alimentary Pharmacology and Therapeutics found that 40% of women diagnosed with celiac had iron-deficiency anemia as their presenting complaint, while diarrhea was the presenting symptom in only 22% of women versus 35% of men. This is clinically significant: if your provider is only looking for gut symptoms, celiac may not even appear on their differential.

Nutrition and Fasting Impact on Celiac Panel Results

The single most consequential preparation fact: you cannot fast gluten before this test. That is the opposite of most lab instructions.

The antibodies measured in the celiac panel, particularly tTG-IgA, are produced in direct response to ongoing gluten ingestion. If you eliminate gluten before testing because you suspect a problem, you may suppress your antibody levels enough to produce a false-negative result within as little as two weeks. The American College of Gastroenterology recommends a gluten-containing diet of at least 10 grams of gluten per day (roughly two slices of bread) for a minimum of six weeks before serology.

Fasting status, by contrast, has no meaningful effect on tTG-IgA or EMA levels. You may eat and drink normally on the day of the blood draw.

How Much Gluten Is Enough Before Testing

| Gluten Source | Approximate Gluten Content | |---|---| | 1 slice standard wheat bread | 4-5 g | | 1 cup cooked pasta | 5-6 g | | 2 plain wheat crackers | 1-2 g | | 1 standard flour tortilla | 4 g |

To reach the 10 g/day threshold recommended for a valid celiac panel, two to three servings of wheat-based food per day is typically sufficient. Specialty gluten products (rye, barley, spelt) also count. Oats are cross-reactive only in a minority of celiacs and do not reliably stimulate antibody production in all patients, so wheat-based foods are the more reliable pre-test choice.

What Suppresses Antibody Levels Falsely

Several factors can push your tTG-IgA toward normal even when celiac disease is active:

• Gluten-free diet: any meaningful reduction in gluten intake before testing
• IgA deficiency: present in roughly 2-3% of women with celiac disease; a low total IgA invalidates the tTG-IgA result entirely and requires DGP-IgG testing instead
• Immunosuppressant medications: corticosteroids, methotrexate, mycophenolate, and biologics all blunt antibody production
• Early disease in children: antibody titers are lower before puberty

A 2020 systematic review in the Cochrane Database confirmed that tTG-IgA sensitivity drops from approximately 93% on a full gluten diet to below 30% after six or more months of a gluten-free diet.

IgA Deficiency: A Women-Specific Note

Selective IgA deficiency affects women and men equally by prevalence, but it is relevant here because women with autoimmune diseases, including thyroid disease and lupus, have higher rates of concurrent IgA deficiency. If your total IgA comes back below 7 mg/dL, your tTG-IgA result is uninterpretable. In that case, DGP-IgG testing is the appropriate alternative per ACG 2023 guidelines.

Normal Ranges, Optimal Ranges, and What "Borderline" Means

Standard Reference Ranges by Antibody

Reference ranges vary by laboratory and assay, but the following are typical:

| Antibody | Negative (Normal) | Weak Positive | Positive | |---|---|---|---| | tTG-IgA | <4 U/mL (varies by lab) | 4-10 U/mL | >10 U/mL | | EMA-IgA | Negative | N/A | Positive | | DGP-IgG | <20 U | 20-30 U | >30 U | | Total IgA | 70-400 mg/dL | N/A | <7 mg/dL = deficiency |

Always compare your result to the reference range printed on your own lab report. LabCorp and Quest use slightly different assay cutoffs.

What "Optimal" Means on the Celiac Panel

The concept of an "optimal" celiac panel range requires clarification, because this test is not designed like a metabolic marker with a sweet spot. There is no health benefit to having an unusually low tTG-IgA as long as it is below the negative cutoff. The goal is: negative and interpretable.

A clinically meaningful framework for women interpreting their celiac panel looks like this:

1. Truly negative: tTG-IgA well below the lab cutoff (in practice, below 2 U/mL on most assays), total IgA within range, EMA negative. No further celiac workup is needed unless you have a first-degree relative with celiac or a high-risk condition such as type 1 diabetes or Down syndrome.

2. Weak positive or borderline: tTG-IgA between 1x and 3x the upper limit of normal. ACG 2023 guidelines recommend reflex testing with EMA-IgA and HLA-DQ2/DQ8 genotyping, plus gastroenterology referral, before any dietary change.

3. Strongly positive: tTG-IgA above 10x the upper limit of normal. ESPGHAN 2020 pediatric guidelines allow diagnosis without biopsy in children at this level, and adult gastroenterologists are increasingly applying similar reasoning in adults with matching symptoms. An adult woman with tTG-IgA >10x ULN, positive EMA, and compatible symptoms should be referred for duodenal biopsy before starting a gluten-free diet.

On Monitoring After Diagnosis

Once you have a confirmed celiac diagnosis and start a gluten-free diet, tTG-IgA is re-measured every 6-12 months to assess mucosal healing. Normalization of tTG-IgA typically takes 12-24 months on a strict gluten-free diet. A 2017 study in the American Journal of Gastroenterology found that persistent tTG-IgA elevation after 24 months of a self-reported gluten-free diet correlated most strongly with ongoing inadvertent gluten exposure, not refractory disease.

Celiac Disease Across Women's Life Stages

Reproductive Years (Ages 15-44)

This is the decade when celiac disease most commonly goes undiagnosed in women because symptoms overlap heavily with premenstrual syndrome, endometriosis, and irritable bowel syndrome. Menstrual irregularities, including oligomenorrhea and amenorrhea, occur in approximately 20% of women with untreated celiac disease, likely driven by malabsorption of zinc, B vitamins, and energy substrates needed for hypothalamic-pituitary-ovarian axis function. A 2010 study in Digestive Diseases and Sciences found that menstrual abnormalities resolved in most women within 12 months of adopting a strict gluten-free diet.

If you are experiencing unexplained irregular periods alongside fatigue, low ferritin, or persistent abdominal bloating, a celiac panel is a reasonable first-line investigation.

Trying to Conceive and Fertility

Undiagnosed celiac disease is found in approximately 2.5-3.5% of women with recurrent pregnancy loss, compared with about 1% in the general population. A meta-analysis in Human Reproduction (2016) found a statistically significant association between untreated celiac disease and spontaneous abortion (OR 1.39), but not between treated celiac disease and pregnancy loss. The association likely relates to nutritional deficiencies, particularly folate, iron, and selenium, that are corrected once a strict gluten-free diet restores intestinal absorption.

ASRM practice guidelines do not yet mandate celiac screening in all women with recurrent pregnancy loss but note that testing is reasonable given the low cost and potential benefit.

Pregnancy and Postpartum

Celiac disease is not a contraindication to pregnancy, but untreated disease significantly increases obstetric risks. A population-based Swedish cohort study published in JAMA (2017) linked undiagnosed celiac disease to preterm birth (OR 1.37), small for gestational age (OR 1.28), and stillbirth risk. Women with a known celiac diagnosis who maintain a strict gluten-free diet have obstetric outcomes that approximate the general population.

Folate supplementation is especially critical. Villous atrophy in the proximal small intestine, the site of folate absorption, means that standard pre-conception folate doses may be insufficient. Some gastroenterologists recommend 5 mg/day (prescription-dose folic acid) rather than the standard 400-800 mcg for women with celiac disease who are planning pregnancy, though this is extrapolated from neural tube defect prevention data rather than a celiac-specific randomized trial.

Postpartum thyroiditis occurs in roughly 5-10% of women in the year after delivery, and the overlap between postpartum thyroiditis and celiac disease is clinically underrecognized. Both are autoimmune conditions, and a 2018 study in Thyroid found a threefold higher prevalence of celiac disease in women with autoimmune thyroid disorders.

Lactation note: Celiac disease itself does not contraindicate breastfeeding. A gluten-free diet during lactation is safe for the infant and does not prevent the development of tolerance. There is no indication to restrict gluten in a breastfeeding mother solely to prevent celiac disease in her infant. Current evidence from the PreventCD trial did not show that timing or method of gluten introduction via breastfeeding altered celiac disease risk in genetically susceptible infants.

Perimenopause

Perimenopause is a second window where undiagnosed celiac disease becomes dangerous for bone health. Estrogen loss accelerates bone resorption, and if celiac disease has simultaneously been impairing calcium and vitamin D absorption for years, the combined effect on bone mineral density can be severe. A 2020 study in Bone found that postmenopausal women with late-diagnosed celiac disease had lumbar spine Z-scores approximately 1.2 standard deviations lower than age-matched controls without celiac disease.

If you are perimenopausal and your DXA scan shows accelerated bone loss that is out of proportion to your age and estrogen status, a celiac panel is worth ordering. Undiagnosed celiac is one of the more treatable causes of secondary osteoporosis.

Postmenopause

In postmenopausal women, the most common presentations of previously undiagnosed celiac disease are osteoporosis, unexplained anemia, and neurological symptoms including peripheral neuropathy. NICE guideline CG86 (updated 2023) recommends celiac testing in adults with unexplained metabolic bone disease.

Celiac and Thyroid: An Underappreciated Overlap

Women with Hashimoto's thyroiditis or Graves' disease have a significantly higher prevalence of celiac disease than the general population. A 2020 meta-analysis in Thyroid found celiac disease prevalence of approximately 4.0% in those with autoimmune thyroid disease, roughly four times higher than the general population rate of around 1%.

The clinical implication is bidirectional. Untreated celiac disease may impair levothyroxine absorption: the proximal small intestine where celiac causes the most villous atrophy is also where levothyroxine is preferentially absorbed. Women on levothyroxine who have persistent hypothyroid symptoms despite adequate dosing, or who require escalating doses, should have a celiac panel checked. A 2001 study in the New England Journal of Medicine demonstrated that switching levothyroxine to a liquid formulation, or timing the dose away from meals, improved absorption in patients with intestinal malabsorption syndromes including celiac disease.

Conversely, a strict gluten-free diet in a woman with both celiac and hypothyroidism may improve levothyroxine absorption enough to require a dose reduction. Thyroid function tests should be rechecked 3-6 months after starting a gluten-free diet.

Celiac, Iron Deficiency, and B12 in Women

Iron deficiency is the most common nutritional deficiency worldwide and disproportionately affects women of reproductive age due to menstrual losses. Celiac disease adds a second layer by impairing iron absorption in the duodenum and proximal jejunum. A 2017 systematic review in Alimentary Pharmacology and Therapeutics found that among women with iron-deficiency anemia and no obvious cause after gynecological evaluation, celiac disease was identified in 5-7% of cases.

The practical implication: if your ferritin remains low despite three months of oral iron supplementation and there is no ongoing blood loss to explain it, a celiac panel should be ordered. Oral iron is absorbed in the same segment of bowel that celiac disease damages first.

B12 deficiency from celiac disease tends to appear later in the disease course, because B12 is absorbed in the terminal ileum rather than the proximal small intestine. Women with long-standing undiagnosed celiac disease may develop B12 deficiency that compounds fatigue, neuropathy, and cognitive symptoms. Measuring serum B12, methylmalonic acid, and homocysteine gives a fuller picture of B12 status than serum B12 alone.

PCOS and Celiac: What the Data Shows

Polycystic ovary syndrome and celiac disease share inflammatory pathways, and women with PCOS may be at slightly higher risk of autoimmune conditions including celiac. However, the evidence for a direct PCOS-celiac link remains limited. A 2019 case-control study in Gynecological Endocrinology found a higher seroprevalence of anti-gliadin antibodies in women with PCOS compared with controls, but did not use the more specific tTG-IgA or biopsy-confirmed diagnosis. This area lacks adequately powered prospective data; the association is plausible but not established. Women with PCOS who also have unexplained anemia, persistent fatigue, or poor response to metformin should have celiac serology checked, but routine screening of all women with PCOS is not yet guideline-supported.

Who Should Get a Celiac Panel (and Who Probably Does Not Need One)

Strong Indications for Testing

• First-degree relative with biopsy-confirmed celiac disease (lifetime risk approximately 10%)
• Iron-deficiency anemia unexplained after gynecological evaluation
• Unexplained infertility or recurrent pregnancy loss
• Unexplained elevation of liver enzymes (ALT/AST)
• Type 1 diabetes (co-occurrence rate approximately 5-8%)
• Autoimmune thyroid disease (Hashimoto's or Graves')
• Symptoms of malabsorption: chronic diarrhea, weight loss, steatorrhea
• Down syndrome, Turner syndrome, or Williams syndrome
• Accelerated bone loss on DXA disproportionate to age and estrogen status
• Peripheral neuropathy or unexplained ataxia with no other cause
• Dermatitis herpetiformis (blistering skin rash)

Lower Yield Situations

• Non-specific fatigue without any of the above
• Irritable bowel syndrome symptoms without anemia, weight loss, or family history
• Elective screening with no risk factors or symptoms

ACG 2023 guidelines advise against population-wide celiac screening given that only one in five serologically positive individuals without symptoms currently benefits from a gluten-free diet. Testing should be targeted.

The Evidence Gap: What We Do Not Know Yet

Women have been historically underrepresented in celiac disease mechanistic trials, particularly regarding hormonal modulation of disease activity. The following questions remain inadequately studied in women specifically:

• Whether estrogen fluctuations during the menstrual cycle or perimenopause alter tTG-IgA titers in women with subclinical or active celiac disease
• The optimal folate dose for pre-conception supplementation in women with celiac disease (current recommendations extrapolate from general malabsorption data)
• Whether the PCOS-celiac connection is causal, co-occurring due to shared autoimmune risk, or spurious

Where data directly from women is absent, this article notes extrapolation. The ACG 2023 celiac guidelines are based largely on trials with mixed-sex populations and do not provide sex-stratified recommendations.